Mufg Securities Americas Inc. Increases Stock Holdings in Eli Lilly and Company $LLY

Mufg Securities Americas Inc. grew its stake in Eli Lilly and Company (NYSE:LLY) by 25.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,434 shares of the company’s stock after purchasing an additional 3,487 shares during the period. Eli Lilly and Company makes up approximately 1.2% of Mufg Securities Americas Inc.’s portfolio, making the stock its 12th biggest holding. Mufg Securities Americas Inc.’s holdings in Eli Lilly and Company were worth $13,590,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at about $27,000. Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company in the second quarter valued at about $31,000. Blume Capital Management Inc. lifted its position in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after purchasing an additional 14 shares during the period. IMG Wealth Management Inc. acquired a new position in Eli Lilly and Company during the 2nd quarter worth approximately $35,000. Finally, TD Capital Management LLC raised its stake in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,058.05 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $1.00 trillion, a price-to-earnings ratio of 69.15, a PEG ratio of 1.21 and a beta of 0.43. The company’s 50 day simple moving average is $855.89 and its 200 day simple moving average is $787.66. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,066.65.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent analyst reports. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Scotiabank began coverage on shares of Eli Lilly and Company in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 target price for the company. Leerink Partnrs upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, November 3rd. Finally, Guggenheim reaffirmed a “buy” rating and issued a $948.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,027.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.